For research use only. Not for human or veterinary use. Supplied as a lyophilized powder for laboratory research.
KPV peptide research focuses on a tripeptide, lysine-proline-valine, that corresponds to the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH) [1]. Researchers became interested in KPV because it kept α-MSH’s effects on inflammatory signaling in experimental models without α-MSH’s pigmentary activity [1]. A 2008 study found that nanomolar KPV inhibited NF-κB and MAP kinase inflammatory signaling in human intestinal epithelial and immune cell lines, and that KPV enters those cells through the PepT1 transporter [2].
What is KPV? Structure
| Property | Value |
|---|---|
| Sequence | Lys-Pro-Val (KPV) [2] |
| Formula / MW | C₁₆H₃₀N₄O₄ / ~342.4 g/mol (PubChem CID 125672) |
| Parent molecule | C-terminal tripeptide of α-MSH (α-MSH 11–13) [1] |
| Form supplied by MFP | Supplied as a lyophilized powder for laboratory research |
KPV and alpha-MSH
α-MSH is a 13-residue peptide derived from proopiomelanocortin. A 2008 Endocrine Reviews article describes its effects on inflammatory pathways, including NF-κB activation, adhesion molecules, cytokine production and inflammatory cell migration, in cell and animal models [1]. The same review identifies KPV as a fragment that retains the anti-inflammatory signaling profile but lacks the pigmentary action, and discusses a related tripeptide, KdPT [1].
KPV studies: mechanism in cell models
The 2008 Gastroenterology study reported [2]:
- Signaling: nanomolar KPV inhibited NF-κB and MAP kinase activation and lowered pro-inflammatory cytokine secretion in Caco2-BBE and HT29-Cl.19A intestinal epithelial cells and Jurkat T cells.
- Transport: KPV uptake was mediated by PepT1, a di- and tripeptide transporter, in epithelial and immune cells. Uptake kinetics were measured with radiolabeled KPV.
- Animal models: the authors also tested KPV in two chemically induced mouse models of intestinal inflammation and reported lower pro-inflammatory cytokine expression.
These are cell-line and mouse results; they do not establish effects in people.
Regulatory status
FDA lists KPV in Category 2 of bulk drug substances nominated for compounding that may present significant safety risks [3]. KPV is not FDA-approved for any use.
Frequently asked questions
KPV is the tripeptide Lys-Pro-Val, the C-terminal fragment of α-MSH [1][2].
In the 2008 study, KPV was taken up through PepT1, a di- and tripeptide transporter expressed in intestinal epithelial and immune cells [2].
Nanomolar KPV inhibited NF-κB and MAP kinase signaling in human cell lines [2].
No. KPV is only the last three residues of the 13-residue α-MSH, and it lacks α-MSH’s pigmentary action [1].
Research materials and certificates
- KPV · KLOW Bundle · COA Library
- Related: GHK-Cu Research · BPC-157 Research
References
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. doi:10.1210/er.2007-0027. PMID: 18612139
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. doi:10.1053/j.gastro.2007.10.026. PMID: 18061177
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of 04/22/2026. fda.gov
Research-use-only disclaimer: All products from My Freedom Peptides are supplied as a lyophilized powder for laboratory research. They are for research use only and not for human or veterinary use. My Freedom Peptides LLC is a chemical supplier. It is not a 503A compounding pharmacy or a 503B outsourcing facility. These statements have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease.
